Empagliflozin directly improves diastolic function in human heart failure

European Journal of Heart Failure

Volumn 20, Issue 12, 2018, Pages 1690-1700

  Pabel, Steffen ^a,b   Wagner, Stefan ^a   Bollenberg, Hannah ^b   Bengel, Philipp ^b   Kovács, Árpád ^d   Schach, Christian ^a   Tirilomis, Petros ^b   Mustroph, Julian ^a   Renner, André ^c   Gummert, Jan ^c   Fischer, Thomas ^b   Van Linthout, Sophie ^e   Tschöpe, Carsten ^e   Streckfuss Bömeke, Katrin ^b   Hasenfuss, Gerd ^b   Maier, Lars S ^a   Hamdani, Nazha ^d   Sossalla, Samuel ^a,b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Contractility; Diastolic dysfunction; Empagliflozin; Heart failure

Indexed keywords

EMPAGLIFLOZIN; REGULATOR PROTEIN; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIAC MUSCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLE; DRUG EFFECT; DRUG RESPONSE; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE CONTRACTILITY; HEART TRABECULAR MUSCLE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MIDDLE AGED; MOUSE; MUSCLE RIGIDITY; MUSCLE TONE; MYOFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SYSTOLE; ANIMAL; BIOPSY; CARDIAC MUSCLE CELL; DIAGNOSTIC IMAGING; DISEASE MODEL; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHARMACOLOGY; ZUCKER RAT;

ANIMALS; BENZHYDRYL COMPOUNDS; BIOPSY; DIASTOLE; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; FEMALE; GLUCOSIDES; HEART FAILURE; HEART VENTRICLES; HUMANS; MALE; MICE; MIDDLE AGED; MYOCARDIAL CONTRACTION; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; RATS, ZUCKER; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; VENTRICULAR FUNCTION, LEFT;

EID: 85055058539     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.1328     Document Type: Article

References (37)

1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117–2128
2. Zinman B, Mathieu C, Kaspers S, Mattheus M, Woerle HJ, Fitchett D. Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time. Eur Heart J 2017;38(Suppl 1):493 (abstr)
3. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia 2016;59:1333–1339
4. Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZ. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation 2017;136:1643–1658
5. Marx N, McGuire DK. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J 2016;37:3192–3200
6. Staels B. Cardiovascular protection by sodium glucose cotransporter 2 inhibitors: potential mechanisms. Am J Cardiol 2017;120(1 Suppl):S28–36
7. Hamdani N, Hervent AS, Vandekerckhove L, Matheeussen V, Demolder M, Baerts L, De Meester I, Linke WA, Paulus WJ, De Keulenaer GW. Left ventricular diastolic dysfunction and myocardial stiffness in diabetic mice is attenuated by inhibition of dipeptidyl peptidase 4. Cardiovasc Res 2014;104:423–431
8. Sossalla S, Wagner S, Rasenack EC, Ruff H, Weber SL, Schondube FA, Tirilomis T, Tenderich G, Hasenfuss G, Belardinelli L, Maier LS. Ranolazine improves diastolic dysfunction in isolated myocardium from failing human hearts--role of late sodium current and intracellular ion accumulation. J Mol Cell Cardiol 2008;45:32–43
9. 2+ /calmodulin-dependent protein kinase II improves contractility in human failing myocardium. Circ Res 2010;107:1150–1161
10. 2+ leak in human cardiac pathology. Circulation 2013;128:970–981
11. 2+ /calmodulin-dependent protein kinase-II in regulating diastolic stress of normal and failing hearts via titin phosphorylation. Circ Res 2013;112:664–674
12. Hamdani N, Bishu KG, von Frieling-Salewsky M, Redfield MM, Linke WA. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc Res 2013;97:464–471
13. Heise T, Seman L, Macha S, Jones P, Marquart A, Pinnetti S, Woerle HJ, Dugi K. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther 2013;4:331–345
14. Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin Pharmacokinet 2014;53:213–225
15. Chen L, Mao Y, Sharp D, Schadt S, Pagels S, Press R, Cheng T, Potchoiba MJ, Collins W. Pharmacokinetics, biotransformation, distribution and excretion of empagliflozin, a sodium-glucose co-transporter (SGLT 2) inhibitor, in mice, rats, and dogs. J Pharm Drug Devel 2015;3:302
16. Lum-Naihe K, Toedebusch R, Mahmood A, Bajwa J, Carmack T, Kumar SA, Ardhanari S, DeMarco VG, Emter CA, Pulakat L. Cardiovascular disease progression in female Zucker Diabetic Fatty rats occurs via unique mechanisms compared to males. Sci Rep 2017;7:17823
17. Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley-Connell A, DeMarco VG. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol 2017;16:9
18. Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E, Hajjar R, Lebeche D. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther 2017;31:233–246
19. Verma S, Garg A, Yan AT, Gupta AK, Al-Omran M, Sabongui A, Teoh H, Mazer CD, Connelly KA. Effect of empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: an important clue to the EMPA-REG OUTCOME trial? Diabetes Care 2016;39:e212–e213
20. Moss RL, Razumova M, Fitzsimons DP. Myosin crossbridge activation of cardiac thin filaments: implications for myocardial function in health and disease. Circ Res 2004;94:1290–1300
21. + exchanger in rats and rabbits. Diabetologia 2017;60:568–573
22. + ]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res 2003;57:1015–1024
23. Hamdani N, Kooij V, van Dijk S, Merkus D, Paulus WJ, Remedios CD, Duncker DJ, Stienen GJ, van der Velden J. Sarcomeric dysfunction in heart failure. Cardiovasc Res 2008;77:649–658
24. van der Velden J. Diastolic myofilament dysfunction in the failing human heart. Pflugers Arch 2011;462:155–163
25. Hamdani N, Paulus WJ, van Heerebeek L, Borbely A, Boontje NM, Zuidwijk MJ, Bronzwaer JG, Simonides WS, Niessen HW, Stienen GJ, van der Velden J. Distinct myocardial effects of beta-blocker therapy in heart failure with normal and reduced left ventricular ejection fraction. Eur Heart J 2009;30:1863–1872
26. van Heerebeek L, Franssen CP, Hamdani N, Verheugt FW, Somsen GA, Paulus WJ. Molecular and cellular basis for diastolic dysfunction. Curr Heart Fail Rep 2012;9:293–302
27. von Lewinski D, Rainer PP, Gasser R, Huber MS, Khafaga M, Wilhelm B, Haas T, Machler H, Rossl U, Pieske B. Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patients. Metabolism 2010;59:1020–1028
28. Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, Luconi M, Mannucci E. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. Int J Cardiol 2017;243:86–90
29. Grempler R, Thomas L, Eckhardt M, Himmelsbach F, Sauer A, Sharp DE, Bakker RA, Mark M, Klein T, Eickelmann P. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14:83–90
30. Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol 2016;15:157
31. Steven S, Oelze M, Hanf A, Kroller-Schon S, Kashani F, Roohani S, Welschof P, Kopp M, Godtel-Armbrust U, Xia N, Li H, Schulz E, Lackner KJ, Wojnowski L, Bottari SP, Wenzel P, Mayoux E, Munzel T, Daiber A. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol 2017;13:370–385
32. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschope C, Leite-Moreira AF, Musters R, Niessen HW, Linke WA, Paulus WJ, Hamdani N. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail 2016;4:312–324
33. Kotter S, Gout L, Von Frieling-Salewsky M, Muller AE, Helling S, Marcus K, Dos Remedios C, Linke WA, Kruger M. Differential changes in titin domain phosphorylation increase myofilament stiffness in failing human hearts. Cardiovasc Res 2013;99:648–656
34. Borbély A, Falcao-Pires I, van Heerebeek L, Hamdani N, Édes I, Gavina C, Leite-Moreira AF, Bronzwaer JG, Papp Z, van der Velden J, Stienen GJ, Paulus WJ. Hypophosphorylation of the stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium. Circ Res 2009;104:780–786
35. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016;18:891–975
36. Westermann D, Kasner M, Steendijk P, Spillmann F, Riad A, Weitmann K, Hoffmann W, Poller W, Pauschinger M, Schultheiss HP, Tschope C. Role of left ventricular stiffness in heart failure with normal ejection fraction. Circulation 2008;117:2051–2060
37. van Riet EE, Hoes AW, Limburg A, Landman MA, van der Hoeven H, Rutten FH. Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail 2014;16:772–777